Research ExplorerPublicationsTransapical aortic valve implantation: mid-term outcome from...

Transapical aortic valve implantation: mid-term outcome from the SOURCE registry

Standard

Transapical aortic valve implantation: mid-term outcome from the SOURCE registry. / Wendler, Olaf; Walther, Thomas; Schroefel, Holger; Lange, Rüdiger; Treede, Hendrik; Fusari, Melissa; Rubino, Paolo; Thomas, Martyn; SOURCE investigators.

In: EUR J CARDIO-THORAC, Vol. 43, No. 3, 03.2013, p. 505-511.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wendler, O, Walther, T, Schroefel, H, Lange, R, Treede, H, Fusari, M, Rubino, P, Thomas, M & SOURCE investigators 2013, 'Transapical aortic valve implantation: mid-term outcome from the SOURCE registry', EUR J CARDIO-THORAC, vol. 43, no. 3, pp. 505-511. https://doi.org/10.1093/ejcts/ezs297

APA

Wendler, O., Walther, T., Schroefel, H., Lange, R., Treede, H., Fusari, M., Rubino, P., Thomas, M., & SOURCE investigators (2013). Transapical aortic valve implantation: mid-term outcome from the SOURCE registry. EUR J CARDIO-THORAC, 43(3), 505-511. https://doi.org/10.1093/ejcts/ezs297

Vancouver

Wendler O, Walther T, Schroefel H, Lange R, Treede H, Fusari M et al. Transapical aortic valve implantation: mid-term outcome from the SOURCE registry. EUR J CARDIO-THORAC. 2013 Mar;43(3):505-511. https://doi.org/10.1093/ejcts/ezs297

Bibtex

@article{581593d970e2410291f4b730741136fe,
title = "Transapical aortic valve implantation: mid-term outcome from the SOURCE registry",
abstract = "OBJECTIVES: Transapical (TA) aortic valve implantation using the Edwards SAPIEN bioprosthesis was commercially introduced in Europe in January 2008. Limited data on the mid-term results are available.METHODS: Using data from the SOURCE-Registry (largest consecutive cohort treated using Edwards SAPIEN bioprosthesis in Europe), we report on the mid-term results (≥30 days-2 years) of TA patients.RESULTS: Between November 2007 and December 2009, a total of 1387 patients from 38 European centres underwent TA aortic valve implantation. The mean follow-up is 14.9 months, with 1004 patients who completed 1 year and 464 patients who completed the 2-year follow-up. The mean age of patients was 80.6 ± 7.1 years with a logistic-EuroSCORE of 27.6%. The main co-morbidities were coronary artery disease (55.8%), previous bypass grafting (25.5%), porcelain aorta (10.2%), previous stroke (6.5%) and peripheral vascular disease (26.4%). A total of 840 patients (60.6%) received a 26 mm and 535 (38.6%) a 23 mm Edwards SAPIEN bioprosthesis. Survivals at 30 days, 1 year and 2 years were 88.7, 73.8 and 65.1%, respectively. Causes of the 276 deaths observed between >30 days and 2-year follow-up were cardiac in 86 patients (31.2%), non-cardiac in 142 (51.4%) and unknown in 48 (17.4%). Cardiac causes of death included heart failure (33.7%), sudden cardiac death (33.7%), myocardial infarct (8.1%), endocarditis (5.8%) and others (18.6%). Non-cardiac deaths were related to pulmonary disease (21.1%), cancer (12.7%), renal failure (11.3%), stroke (10.6%), gastrointestinal disease (7.7%) and others (36.6%). Using univariable and multivariable analyses, logistic EuroSCORE, renal insufficiency and liver diseases were identified as independent predictors of 2-year mortality.CONCLUSIONS: These results demonstrate that in elderly patients with severe co-morbidities, TA aortic valve implantation results in excellent mid-term results. Causes of death during the mid-term follow-up are mainly non-cardiac and related to co-morbidities.",
keywords = "Aged, Aged, 80 and over, Aortic Valve/surgery, Aortic Valve Stenosis/surgery, Cardiac Catheterization/adverse effects, Cohort Studies, Female, Heart Valve Prosthesis Implantation/adverse effects, Humans, Kaplan-Meier Estimate, Male, Minimally Invasive Surgical Procedures/adverse effects, Multivariate Analysis, Registries",
author = "Olaf Wendler and Thomas Walther and Holger Schroefel and R{\"u}diger Lange and Hendrik Treede and Melissa Fusari and Paolo Rubino and Martyn Thomas and {SOURCE investigators}",
year = "2013",
month = mar,
doi = "10.1093/ejcts/ezs297",
language = "English",
volume = "43",
pages = "505--511",
journal = "EUR J CARDIO-THORAC",
issn = "1010-7940",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Transapical aortic valve implantation: mid-term outcome from the SOURCE registry

AU - Wendler, Olaf

AU - Walther, Thomas

AU - Schroefel, Holger

AU - Lange, Rüdiger

AU - Treede, Hendrik

AU - Fusari, Melissa

AU - Rubino, Paolo

AU - Thomas, Martyn

AU - SOURCE investigators

PY - 2013/3

Y1 - 2013/3

N2 - OBJECTIVES: Transapical (TA) aortic valve implantation using the Edwards SAPIEN bioprosthesis was commercially introduced in Europe in January 2008. Limited data on the mid-term results are available.METHODS: Using data from the SOURCE-Registry (largest consecutive cohort treated using Edwards SAPIEN bioprosthesis in Europe), we report on the mid-term results (≥30 days-2 years) of TA patients.RESULTS: Between November 2007 and December 2009, a total of 1387 patients from 38 European centres underwent TA aortic valve implantation. The mean follow-up is 14.9 months, with 1004 patients who completed 1 year and 464 patients who completed the 2-year follow-up. The mean age of patients was 80.6 ± 7.1 years with a logistic-EuroSCORE of 27.6%. The main co-morbidities were coronary artery disease (55.8%), previous bypass grafting (25.5%), porcelain aorta (10.2%), previous stroke (6.5%) and peripheral vascular disease (26.4%). A total of 840 patients (60.6%) received a 26 mm and 535 (38.6%) a 23 mm Edwards SAPIEN bioprosthesis. Survivals at 30 days, 1 year and 2 years were 88.7, 73.8 and 65.1%, respectively. Causes of the 276 deaths observed between >30 days and 2-year follow-up were cardiac in 86 patients (31.2%), non-cardiac in 142 (51.4%) and unknown in 48 (17.4%). Cardiac causes of death included heart failure (33.7%), sudden cardiac death (33.7%), myocardial infarct (8.1%), endocarditis (5.8%) and others (18.6%). Non-cardiac deaths were related to pulmonary disease (21.1%), cancer (12.7%), renal failure (11.3%), stroke (10.6%), gastrointestinal disease (7.7%) and others (36.6%). Using univariable and multivariable analyses, logistic EuroSCORE, renal insufficiency and liver diseases were identified as independent predictors of 2-year mortality.CONCLUSIONS: These results demonstrate that in elderly patients with severe co-morbidities, TA aortic valve implantation results in excellent mid-term results. Causes of death during the mid-term follow-up are mainly non-cardiac and related to co-morbidities.

AB - OBJECTIVES: Transapical (TA) aortic valve implantation using the Edwards SAPIEN bioprosthesis was commercially introduced in Europe in January 2008. Limited data on the mid-term results are available.METHODS: Using data from the SOURCE-Registry (largest consecutive cohort treated using Edwards SAPIEN bioprosthesis in Europe), we report on the mid-term results (≥30 days-2 years) of TA patients.RESULTS: Between November 2007 and December 2009, a total of 1387 patients from 38 European centres underwent TA aortic valve implantation. The mean follow-up is 14.9 months, with 1004 patients who completed 1 year and 464 patients who completed the 2-year follow-up. The mean age of patients was 80.6 ± 7.1 years with a logistic-EuroSCORE of 27.6%. The main co-morbidities were coronary artery disease (55.8%), previous bypass grafting (25.5%), porcelain aorta (10.2%), previous stroke (6.5%) and peripheral vascular disease (26.4%). A total of 840 patients (60.6%) received a 26 mm and 535 (38.6%) a 23 mm Edwards SAPIEN bioprosthesis. Survivals at 30 days, 1 year and 2 years were 88.7, 73.8 and 65.1%, respectively. Causes of the 276 deaths observed between >30 days and 2-year follow-up were cardiac in 86 patients (31.2%), non-cardiac in 142 (51.4%) and unknown in 48 (17.4%). Cardiac causes of death included heart failure (33.7%), sudden cardiac death (33.7%), myocardial infarct (8.1%), endocarditis (5.8%) and others (18.6%). Non-cardiac deaths were related to pulmonary disease (21.1%), cancer (12.7%), renal failure (11.3%), stroke (10.6%), gastrointestinal disease (7.7%) and others (36.6%). Using univariable and multivariable analyses, logistic EuroSCORE, renal insufficiency and liver diseases were identified as independent predictors of 2-year mortality.CONCLUSIONS: These results demonstrate that in elderly patients with severe co-morbidities, TA aortic valve implantation results in excellent mid-term results. Causes of death during the mid-term follow-up are mainly non-cardiac and related to co-morbidities.

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve/surgery

KW - Aortic Valve Stenosis/surgery

KW - Cardiac Catheterization/adverse effects

KW - Cohort Studies

KW - Female

KW - Heart Valve Prosthesis Implantation/adverse effects

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Minimally Invasive Surgical Procedures/adverse effects

KW - Multivariate Analysis

KW - Registries

U2 - 10.1093/ejcts/ezs297

DO - 10.1093/ejcts/ezs297

M3 - SCORING: Journal article

C2 - 22648920

VL - 43

SP - 505

EP - 511

JO - EUR J CARDIO-THORAC

JF - EUR J CARDIO-THORAC

SN - 1010-7940

IS - 3

ER -